Developing hybrid hydrogel dressings with anti‐inflammatory, antioxidant, angiogenetic, and antibiofilm activities with higher bone tissue penetrability to accelerate diabetic wound healing and prevent diabetic foot osteomyelitis (DFO) is highly desirable in managing diabetic wounds. Herein, the glycopeptide teicoplanin is used for the first time as a green reductant to chemically reduce graphene oxide (GO). The resulting teicoplanin‐decorated reduced graphene oxide (rGO) is incorporated into a mixture of silk proteins (SP) and crosslinked with genipin to yield a physicochemically crosslinked rGO‐SP hybrid hydrogel. This hybrid hydrogel exhibits high porosity, self‐healing, shear‐induced thinning, increased cell proliferation and migration, and mechanical properties suitable for tissue engineering. Moreover, the hybrid hydrogel eradicates bacterial biofilms with a high penetrability index in agar and hydroxyapatite discs covered with biofilms, mimicking bone tissue. In vivo, the hybrid hydrogel accelerates the healing of non‐infected wounds in a diabetic rat and infected wounds in a diabetic mouse by up‐regulating anti‐inflammatory cytokines and down‐regulating matrix metalloproteinase‐9, promoting M2 macrophage polarization and angiogenesis. The implantation of hybrid hydrogel into the infected site of mouse tibia improves bone regeneration. Hence, the rGO‐SP hybrid hydrogel can be a promising wound dressing for treating infectious diabetic wounds, providing a further advantage in preventing DFO.This article is protected by copyright. All rights reserved